Fanconi anemia

What is Fanconi anemia?

Fanconi anemia (FA) is a rare inherited disorder that primarily affects the bone marrow’s ability to produce blood cells, leading to progressive bone marrow failure. This multisystem condition also causes physical abnormalities, growth delays, and significantly increases the risk of cancer, particularly acute myeloid leukemia and solid tumors. FA affects approximately 1 in 130,000 people worldwide, making it one of the most common inherited bone marrow failure syndromes. The condition is caused by mutations in genes responsible for DNA repair, leading to chromosomal instability and cellular dysfunction.

Key statistics

Symptoms

Growth retardation, bone marrow failure, radial ray defects, microcephaly, developmental delays, café-au-lait spots, hypogonadism, kidney abnormalities, hearing loss, increased cancer susceptibility.

Fanconi anemia presents with a wide spectrum of symptoms that can vary significantly between individuals. Physical abnormalities often become apparent in early childhood and may include short stature, abnormalities of the thumbs and radial bones (radial ray defects), small head size (microcephaly), and distinctive facial features. Skin abnormalities such as café-au-lait spots, areas of increased or decreased pigmentation, and unusual skin patterns are common.

The most serious manifestation is progressive bone marrow failure, typically developing between ages 5-15 years. This leads to low blood cell counts affecting red blood cells (anemia), white blood cells (increased infection risk), and platelets (bleeding and bruising). Patients may experience fatigue, weakness, frequent infections, easy bruising, and prolonged bleeding from minor cuts.

Submit Your Paper

Additional complications include kidney abnormalities, heart defects, hearing impairment, developmental delays, and reproductive system abnormalities leading to fertility issues. Perhaps most concerning is the dramatically increased risk of developing cancers, particularly acute myeloid leukemia in childhood and solid tumors including head and neck cancers in early adulthood.

Causes and risk factors

Fanconi anemia is caused by mutations in genes belonging to the FANC gene family, with at least 23 different FA genes identified to date. The most commonly affected genes include FANCA (60-70% of cases), FANCC (10-15%), and FANCG (8-10%). Most types follow an autosomal recessive inheritance pattern, meaning two copies of the mutated gene must be present for the condition to manifest. However, FANCB follows X-linked inheritance.

These genes are crucial for the FA DNA repair pathway, which helps cells respond to DNA damage. When this pathway is disrupted, cells accumulate DNA damage and become prone to chromosomal breakage, leading to the various manifestations of FA.

The primary risk factor is having parents who are both carriers of FA gene mutations. Certain populations have higher carrier frequencies, including Ashkenazi Jewish, Spanish Romani, and South African Afrikaner populations, where founder effects have concentrated specific mutations.

Prevention

As Fanconi anemia is an inherited genetic condition, it cannot be prevented through lifestyle modifications or environmental interventions. However, genetic counseling and testing play crucial roles in family planning for at-risk couples.

Carrier screening is available for individuals with family history of FA or those from high-risk populations. Preimplantation genetic diagnosis (PGD) can be performed during in vitro fertilization to select embryos without FA mutations. Prenatal diagnosis through chorionic villus sampling or amniocentesis is also possible for pregnancies at risk.

For families with an affected child, genetic counseling can provide information about recurrence risks and reproductive options, including the possibility of conceiving a child who could serve as an HLA-matched sibling donor for bone marrow transplantation.

Complications

Without appropriate treatment, Fanconi anemia leads to severe, life-threatening complications. Progressive bone marrow failure results in severe anemia requiring regular blood transfusions, dangerous bleeding due to low platelet counts, and overwhelming infections from white blood cell deficiency.

The dramatically increased cancer risk represents the most serious long-term complication. Patients have a 500-700 fold increased risk of acute myeloid leukemia compared to the general population, with most cases occurring before age 20. Solid tumors, particularly squamous cell carcinomas of the head, neck, and anogenital regions, typically develop in early adulthood.

Growth failure and endocrine dysfunction often persist into adulthood, affecting final height and reproductive function. Kidney problems may progress to renal failure, and heart defects can cause cardiovascular complications. The cumulative effect of these complications significantly impacts quality of life and survival.

Diagnosis

Diagnosis of Fanconi anemia requires a combination of clinical assessment, specialized laboratory testing, and genetic analysis. The hallmark diagnostic test is the chromosomal breakage test, which exposes patient cells to DNA cross-linking agents like mitomycin C or diepoxybutane. FA cells show characteristic chromosomal breakage and aberrations when exposed to these agents.

Complete blood count typically reveals progressive cytopenias affecting multiple cell lines. Bone marrow biopsy may show hypocellularity and dysplastic changes. Flow cytometry can assess for clonal hematopoietic populations that may indicate malignant transformation.

Genetic testing through comprehensive FA gene panel sequencing or whole exome sequencing can identify specific mutations and confirm the diagnosis. This information is crucial for genetic counseling and family planning.

Additional evaluations include imaging studies to assess for structural abnormalities of the kidneys, heart, and skeletal system. Regular monitoring includes cancer surveillance protocols and assessment of endocrine function.

Treatment

Treatment of Fanconi anemia requires a multidisciplinary approach addressing both the hematologic manifestations and associated complications. For bone marrow failure, oxymetholone and other androgens can temporarily improve blood counts in some patients, though responses are often partial and temporary.

Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for the bone marrow failure component. Best outcomes are achieved with HLA-matched sibling donors, though alternative donor sources including matched unrelated donors and cord blood are increasingly used. Conditioning regimens must be carefully modified due to FA patients’ increased sensitivity to chemotherapy and radiation.

Supportive care includes regular blood transfusions for severe anemia, platelet transfusions for bleeding, and prophylactic antibiotics for infection prevention. Iron chelation therapy with deferasirox or deferoxamine may be necessary for patients receiving chronic transfusions.

Growth hormone therapy can improve height in some patients. Cancer treatment requires specialized protocols accounting for FA patients’ increased sensitivity to DNA-damaging therapies and higher risk of secondary cancers.

Prognosis

The prognosis for Fanconi anemia has improved significantly with advances in supportive care and transplantation techniques, though it remains guarded due to the high cancer risk. Without treatment, most patients with severe bone marrow failure do not survive beyond the second decade of life.

Hematopoietic stem cell transplantation can cure the bone marrow failure, with overall survival rates of 85-90% for patients receiving transplants from matched sibling donors. However, the underlying DNA repair defect persists, maintaining the increased cancer risk throughout life.

Long-term survivors face ongoing challenges including late effects of transplant conditioning, endocrine dysfunction, and the need for lifelong cancer surveillance. The median survival has improved to approximately 30 years, with many patients now surviving well into adulthood with appropriate management.

Quality of life

Living with Fanconi anemia requires ongoing medical management and lifestyle adaptations. Patients must maintain regular follow-up care for monitoring blood counts, cancer surveillance, and management of complications. A healthy lifestyle including good nutrition, appropriate physical activity within limitations, and avoiding known carcinogens like tobacco and excessive alcohol is essential.

Sun protection is particularly important due to increased skin cancer risk. Patients should use broad-spectrum sunscreen, protective clothing, and limit sun exposure. Regular dental care and oral cancer screening are crucial given the high risk of head and neck cancers.

Educational and vocational planning should account for potential cognitive effects and physical limitations. Many patients can participate in regular schooling and employment with appropriate accommodations. Psychological support and counseling can help patients and families cope with the chronic nature of the condition and cancer anxiety.

Social connections through patient organizations and support groups provide valuable peer support and practical information about living with FA.

Pregnancy and fertility

Fertility issues are common in Fanconi anemia, affecting both men and women. Hypogonadism and delayed puberty are frequent, often requiring hormone replacement therapy. Women may experience early menopause and irregular menstrual cycles, while men may have reduced sperm production and testosterone deficiency.

For women who become pregnant, close monitoring is essential due to potential complications from low blood counts and the need to modify medications. Genetic counseling is crucial to discuss the 25% risk of having an affected child with each pregnancy.

Assisted reproductive technologies may be necessary, and preimplantation genetic diagnosis can help ensure unaffected offspring. Fertility preservation should be discussed before conditioning regimens for transplantation, as these treatments can cause permanent infertility.

Children

Children with Fanconi anemia require specialized pediatric care addressing growth and development, educational needs, and the transition to adult care. Growth failure is common and may benefit from growth hormone therapy after careful evaluation of cancer risks.

Developmental delays affect approximately 10% of patients and may require special education services or accommodations. Regular developmental assessments and early intervention services can optimize outcomes.

Family education about recognizing signs of worsening anemia, bleeding, or infection is essential. Children should receive modified vaccination schedules avoiding live vaccines if immunocompromised, and careful attention to infection prevention.

The transition to adult care should begin in adolescence, ensuring continuity of specialized FA management and cancer surveillance protocols.

When to see a doctor

Urgent medical attention is needed for signs of severe bone marrow failure including persistent fever, unusual bleeding or bruising, severe fatigue, or signs of infection that don’t improve with standard treatment. Any new lumps, sores that don’t heal, or changes in skin lesions require prompt evaluation due to cancer risk.

Routine care includes regular monitoring with a hematologist familiar with FA, typically every 3-6 months for blood count monitoring and annual comprehensive evaluations. Cancer surveillance protocols should begin in childhood and continue throughout life.

Parents should seek evaluation for children showing growth delays, developmental concerns, or physical abnormalities suggestive of FA, particularly with a family history of the condition.

Regional context

While Fanconi anemia occurs worldwide, specific mutation frequencies vary among populations. Limited data exists regarding prevalence in the Caucasus region, though isolated cases have been reported in Georgia and Armenia. The Global Medical Journal welcomes contributions from healthcare providers and researchers in the Eastern Mediterranean and Caucasus regions to better understand regional patterns of FA and improve local care capabilities.

Establishing regional registries and collaborative networks could improve outcomes through shared expertise and coordinated research efforts.

Research and clinical trials

Active research focuses on gene therapy approaches, novel conditioning regimens for transplantation, and cancer prevention strategies. Gene therapy trials using viral vectors to correct FA gene defects show promise but face challenges related to the multiple genes involved and cellular sensitivity.

Studies of reduced-intensity conditioning regimens aim to minimize transplant toxicity while maintaining efficacy. Research into cancer prevention includes investigations of antioxidants and cellular protectants.

Current clinical trials can be found at ClinicalTrials.gov using search terms “Fanconi anemia.” The Fanconi Anemia Research Fund maintains a comprehensive database of ongoing research initiatives and facilitates patient participation in studies.

Frequently asked questions

How is Fanconi anemia inherited?

Most types follow autosomal recessive inheritance, requiring both parents to be carriers. Each child of carrier parents has a 25% chance of being affected, 50% chance of being a carrier, and 25% chance of being unaffected and not a carrier.

Can Fanconi anemia be cured?

Bone marrow transplantation can cure the blood problems but doesn’t eliminate the underlying DNA repair defect or cancer risk. It remains the best treatment for severe bone marrow failure.

What is the life expectancy with Fanconi anemia?

Life expectancy has improved significantly with better care, with median survival now around 30 years. Many patients live longer with appropriate treatment and cancer surveillance.

Are all children with Fanconi anemia born with physical abnormalities?

No, about 25-40% of patients have no obvious physical abnormalities at birth, making early diagnosis challenging. Some patients are only diagnosed when blood problems develop.

Can people with Fanconi anemia have children?

While fertility may be reduced, many people with FA can have children. Genetic counseling and testing options including preimplantation genetic diagnosis can help ensure healthy offspring.

Support and resources

Fanconi Anemia Research Fund
Website: fanconi.org
Comprehensive patient support, research funding, and educational resources.

International Fanconi Anemia Registry
Website: rockefeller.edu/fanconi
Clinical database and research coordination.

National Organization for Rare Disorders (NORD)
Website: rarediseases.org
Patient advocacy and rare disease information.

Orphanet
Website: orpha.net
European reference portal for rare diseases.

EURORDIS – Rare Diseases Europe
Website: eurordis.org
European alliance of rare disease patient organizations.

Related conditions

Dyskeratosis congenita
Diamond-Blackfan anemia
Shwachman-Diamond syndrome
Severe congenital neutropenia
Aplastic anemia

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.